Evidence map›Paper›PMID 27977797›Full record

Trial reportPloS one2016

No Positive Association between Vitamin D Level and Immune Responses to Hepatitis B and Streptococcus pneumoniae Vaccination in HIV-Infected Adults.

Jean-Paul Viard, Alex Assuied, Yves Lévy, Jean-Claude Souberbielle, Rodolphe Thiébaut, Fabrice Carrat, Geneviève Chêne, Odile Launay, Laura Richert

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Jean-Paul ViardAPHP, Centre de diagnostic et de Thérapeutique, Hôtel-Dieu, Paris, France.
Alex AssuiedINSERM, ISPED, Centre INSERM U1219, Bordeaux, France.
Yves LévyEquipe 16, INSERM U955, Créteil, France.
Jean-Claude SouberbielleService d'explorations fonctionnelles, Hôpital Necker, APHP, Paris France.
Rodolphe ThiébautINSERM, ISPED, Centre INSERM U1219, Bordeaux, France.
Fabrice CarratINSERM U1136, Paris, France.
Geneviève ChêneINSERM, ISPED, Centre INSERM U1219, Bordeaux, France.
Odile LaunayINSERM, CIC 1417, F-CRIN, I-REIVAC, Paris, France.
Laura RichertINSERM, ISPED, Centre INSERM U1219, Bordeaux, France.ORCID http://orcid.org/0000-0002-7682-2225
Inserm · FRDélégation Paris 5 · FRInstitut national de recherche en sciences et technologies du numérique · FRHôpital Necker-Enfants Malades · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess whether higher 25-hydroxyvitamin D (25OHD) levels are associated with subsequent better immune responses to hepatitis B and Streptococcus pneumoniae vaccination in HIV-infected patients.

methods25OHD was measured on stored baseline plasma samples from two randomized vaccine trials in HIV-infected adults: the ANRS HB03 VIHVAC B trial and an immunological sub-study of the ANRS 114-PNEUMOVAC trial. In ANRS HB03 VIHVAC B, participants received three or four doses of recombinant HBV vaccine strategies. Anti-HBs IgG titers were measured four weeks after the last injection. Associations between baseline 25OHD levels and ordered IgG response categories were analyzed in multivariable proportional odds models. In the ANRS 114-PNEUMOVAC sub-study, two strategies of pneumococcal vaccination were tested, cellular immune responses were measured at repeated time points, and IgG responses four weeks after the last vaccine injection. Exploratory statistical analyses were performed on this sub-study data set.

resultsThree hundred and thirty-nine ANRS HB03 VIHVAC B and 25 ANRS 114-PNEUMOVAC sub-study participants were included in the analyses. Median age in each of the two studies was 43 years, 68% were male, and 77-92% on antiretroviral treatment. Median 25OHD level was 18 ng/mL (IQR: 12-25) and 24 ng/mL (IQR: 13-32) in the two trial populations, respectively. In the multivariable model, there was no significant association between baseline 25OHD level and vaccine responses in ANRS HB03 VIHVAC B (proportional odds ratio 0.83 per 10 ng/mL 25OHD increase; 95% confidence interval 0.65-1.07, p = 0.14). Exploratory analyses of ANRS 114-PNEUMOVAC showed consistent results.

conclusionThis study does not support a positive association between 25OHD and immune responses to hepatitis B or pneumococcal vaccination in HIV-infected patients.

Indexed as

AdultFemaleHepatitis BHepatitis B AntibodiesHepatitis B VaccinesHumansImmunoglobulin GMaleMiddle AgedPneumococcal VaccinesStreptococcus pneumoniaeVitamin D25-hydroxyvitamin DHepatitis B AntibodiesHepatitis B VaccinesImmunoglobulin GPneumococcal VaccinesVitamin D

Identifiers

PMID27977797
PMCPMC5158187
OpenAlexW2561220593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.